Topline results, 20252026
It is a prescriptiononly treatment used to support weight loss and improve metabolic health, and long-term monitoring remains good practice as part of safe use
Week 1-4 Mild appetite reduction, possible nausea during initial dose Month 2-3 Noticeable weight loss (5-10% typical), improved satiety Month 4-6 Continued weight loss (10-15% common), stable glucose levels Week 0-0 Weight loss plateau possible, focus on maintenance Week 0-0 Blood sugar improvements within 1-2 weeks Cheat Sheets Featuring GLP-1 (Semaglutide) See how GLP-1 (Semaglutide) fits into a broader research stack with these free downloadable cheat sheets

Wegovy highlights of prescribing information, Food and Drug Administration (2024) Trulicity highlights of prescribing information, Food and Drug Administration (2022) An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg, Diabetes, Obesity and Metabolism (2021) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) The effect of dulaglutide on glycemic and weight control in patients with type 2 diabetes, Medicine and Pharmacy Reports (2023) Label: Wegovy, DailyMed (2024) Label: Trulicity, DailyMed (2023) GLP-1 receptor agonists and the risk of thyroid cancer, Diabetes Care (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice